跳转至内容
Merck
CN

L6545

Sigma-Aldrich

来曲唑

≥98% (HPLC), powder, non-steroidal aromatase inhibitor

别名:

4,4′-(1H-1,2,4-三唑-1-基亚甲基)双苄腈

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H11N5
分子量:
285.30
MDL编号:
UNSPSC代码:
51111800
PubChem化学物质编号:
NACRES:
NA.77

product name

来曲唑, ≥98% (HPLC)

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to off-white

溶解性

DMSO: >50 mg/mL

创始人

Novartis

储存温度

2-8°C

SMILES字符串

N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3

InChI

1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H

InChI key

HPJKCIUCZWXJDR-UHFFFAOYSA-N

基因信息

human ... CYP19A1(1588)

正在寻找类似产品? 访问 产品对比指南

应用

来曲唑已用于:
  • 在类器官生长试验中测定其抑制力(48)
  • 研究类固醇受体共激活因子1(SRC-1)介导的海马PSD-95内源性雌激素调节作用(49)
  • 研究其对肿瘤诱导的痛觉过敏的作用 (50)
  • 对大鼠进行激素干预(51)研究其对脂质运载蛋白-2(Lcn2)的作用(52)研究其对机械痛觉过敏和芳香化酶表达的作用(53)

生化/生理作用

来曲唑是一种佐剂,可用于治疗乳腺癌。
来曲唑是第三代非甾体芳香酶抑制剂。 它是芳香酶系统的竞争性抑制剂,因此可抑制雄激素向雌激素转化。来曲唑通过竞争性结合到该酶的细胞色素P450亚基的血红素上而抑制芳香酶,导致所有组织中雌激素的生物合成减少。

特点和优势

该化合物是受体分类及信号转导手册上核受体(类固醇)页面上的特色化合物。想要浏览手册的其他页面, 请单击此处
该化合物是由 Novartis开发。浏览其他医药开发的化合物和已批准的药物/候选药物清单,请点击此处

象形图

Health hazard

警示用语:

Warning

危险声明

危险分类

Repr. 2 - STOT RE 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Drugs for Pregnant and Lactating Women E-Book (2009)
Natalia Lagunas et al.
Frontiers in neuroanatomy, 16, 902218-902218 (2022-07-12)
Sex steroid hormones, such as androgens and estrogens, are known to exert organizational action at perinatal periods and activational effects during adulthood on the brain and peripheral tissues. These organizational effects are essential for the establishment of biological axes responsible
Bianca Posocco et al.
PloS one, 15(2), e0228822-e0228822 (2020-02-08)
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice
Mothaffar F Rimawi et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(14), 1726-1731 (2013-04-10)
We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade
Rob Riemsma et al.
Current medical research and opinion, 28(8), 1263-1279 (2012-06-29)
Third-generation aromatase inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced breast cancer compared with tamoxifen. For HR+, HER2+ MBC, combination of an AI with an anti-HER2 agent (lapatinib or trastuzumab) has shown clinical benefit. Six databases were

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门